Spadaro M, Tilia G, Massara M C, Damiani A, Parisi L, Tomelleri G, D'Offizi G, Morocutti C
Istituto di Clinica delle Malattie Nervose e Mentali, Università di Roma La Sapienza.
Ital J Neurol Sci. 1993 Jun;14(5):369-74. doi: 10.1007/BF02340724.
The occurrence of muscular pathologies in AZT treated subjects has been evaluated in 67 HIV seropositive outpatients (56 AZT-treated and 11 untreated controls) in a neurological clinical and paraclinical follow-up study. Standard electromyographic and electrodiagnostic examinations, together with muscle enzyme determination, were performed in every subject, and periodically repeated at fixed intervals; in 11 patients a muscle biopsy sample was also obtained. An AZT-related myopathy was diagnosed in 8 biopsied cases; 9 more patients were considered to have AZT myopathy on clinical, EMG and ex juvantibus criteria. Statistical analysis showed that treatment duration was more relevant to the development of the myopathy than AZT dosage, though an individual predisposition could not be excluded, at least in a small number of cases. The risk of developing a toxic myopathy will therefore have to be considered when evaluating long-term effects of AZT therapy.
在一项神经科临床和辅助检查的随访研究中，对67名HIV血清阳性门诊患者（56名接受齐多夫定治疗，11名未治疗的对照者）发生的肌肉病变情况进行了评估。对每位受试者进行了标准肌电图和电诊断检查以及肌肉酶测定，并定期以固定间隔重复进行；11名患者还获取了肌肉活检样本。在8例活检病例中诊断出与齐多夫定相关的肌病；另外9名患者根据临床、肌电图和辅助标准被认为患有齐多夫定肌病。统计分析表明，治疗持续时间比齐多夫定剂量与肌病的发生更相关，不过至少在少数病例中不能排除个体易感性。因此，在评估齐多夫定治疗的长期效果时，必须考虑发生中毒性肌病的风险。
